



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 17:44
Last Report Issued 05/13/2019 08:06

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2538B-POS
Patient ID 2538B-POS
Chain 18001908
DOB Not Given
Sex Not Given
Workorder 18001908
Received 11/21/2018

Lab ID 18001908-001
Matrix Blood
Patient Name 2538B-POS
Patient ID 2538B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|-----------------------|--------|-------|-----------------|-------|
|-----------------------|--------|-------|-----------------|-------|

2538B Loxapine, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

| | | | | |
|----------------------|----|-------|-----|--|
| Loxapine | 50 | ng/mL | 5.0 | |
| Synonym(s): Adasuve® | | | | |

With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes. The blood to plasma ratio is not known.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.